目的 探索振源膠囊聯(lián)合環(huán)磷腺苷治療冠心病慢性心力衰竭的治療效果。方法 選取2014年2月-2017年6月于山陽(yáng)縣人民醫(yī)院和西安交通大學(xué)第一附屬醫(yī)院接受治療的冠心病慢性心力衰竭患者284例，隨機(jī)分為對(duì)照組和治療組，每組各142例。對(duì)照組患者靜脈注射注射用環(huán)磷腺苷，35 mg加入5%葡萄糖注射液250 mL，1次/d。治療組患者在對(duì)照組的基礎(chǔ)上飯后口服振源膠囊，2粒/次，3次/d。兩組患者均治療30 d。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者臨床指標(biāo)、心功能改善情況和不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為89.44%、98.59%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者腦鈉肽（BNP）和C反應(yīng)蛋白（CRP）水平均明顯降低，6 min步行距離明顯增加，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者臨床指標(biāo)改善情況明顯優(yōu)于對(duì)照組（P<0.05）。治療后，兩組患者左室射血分?jǐn)?shù)（LVEF）明顯升高，左室收縮末期內(nèi)徑（LVESD）和左室舒張末期內(nèi)徑（LVEDD）明顯降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者心功能改善情況明顯優(yōu)于對(duì)照組（P<0.05）。治療過(guò)程中，治療組患者的不良反應(yīng)例數(shù)明顯少于對(duì)照組的，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 振源膠囊聯(lián)合環(huán)磷腺苷治療冠心病慢性心力衰竭患者療效顯著，能夠有效改善患者心功能，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the therapeutic effect of Zhenyuan Capsules combined with adenosine monophosphate in treatment of chronic heart failure of coronary heart disease. Methods Patients (284 cases) with chronic heart failure of coronary heart disease in Shanyang County People's Hospital and the First Affiliated Hospital of Xi'an Jiaotong University from February 2014 to June 2017 were randomly divided into control and treatment groups, and each group had 142 cases. Patients in the control group were iv administered with Adenosine Cyclophosphate for injection, 35 mg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were po administered with Zhenyuan Capsules on the basis of the control group after meals, 2 grains/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy was evaluated, and the clinical indicators, the improvement of cardiac function and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 89.44% and 98.59%, respectively, and there were differences between two groups (P<0.05). After treatment, the BNP and CRP levels in two groups were significantly decreased, but 6 min walking distance was significantly increased, and there were differences in the same group (P<0.05). And the improvement of the clinical indicators in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the LVEF in two groups was significantly increased, but the LVEDD and LVESD were significantly decreased, and there were differences in the same group (P<0.05). And the improvement of cardiac function in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). During the treatment, patients occurred adverse reactions in the treatment were significantly less than those in the control group, with significant difference between two groups (P<0.05). Conclusion Zhenyuan Capsules combined with adenosine monophosphate has significant effect in treatment of chronic heart failure of coronary heart disease, can effectively improve the heart function, which has a certain clinical application value.